NCT01426412

A Study of LY3015014 in Healthy Participants With Elevated Low Density Lipoprotein Cholesterol

A Single-Dose, Dose-Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of LY3015014 in Subjects With Elevated LDL-C

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 69 (actual)
• Sponsor: Eli Lilly and Company · Industry
• Sex: All
• Age: 18 Years – 65 Years
• Healthy volunteers: Accepted

Summary

This is a study in otherwise healthy Japanese and non-Japanese participants with elevated low density lipoprotein cholesterol (LDL-C). Following single doses of LY3015014, the safety and tolerability of the drug, how the body handles the drug, and the drug's effect on the body will be evaluated. Participants will remain in the study for approximately up to 6 months.

Conditions

• Hyperlipidemia

Interventions

Type	Name	Description
DRUG	LY3015014 IV	Administered IV over 30-90 minutes
DRUG	Placebo IV	Administered IV only over 30-90 minutes
DRUG	LY3015014 SC	Administered SC
DRUG	Placebo SC	Administered SC

Timeline

• Start date: 2011-09-01
• Primary completion: 2013-06-01
• Completion: 2013-06-01
• First posted: 2011-08-31
• Last updated: 2019-04-05
• Results posted: 2019-04-05

Locations

3 sites across 1 country: United States